Purpose: To explore the applicability of the epidemiology-based mortality score in status epilepticus (EMSE) and the status epilepticus severity score (STESS) in predicting hospital mortality in patients with status epilepticus (SE) in western China. Furthermore, we sought to compare the abilities of the two scales to predict mortality from convulsive status epilepticus (CSE) and non-convulsive status epilepticus (NCSE). Method: Patients with epilepsy (n = 253) were recruited from the West China Hospital of Sichuan University from January 2012 to January 2016. The EMSE and STESS for all patients were calculated immediately after admission. The main outcome was in-hospital death. The predicted values were analysed using SPSS 22.0 receiver operating characteristic (ROC) curves. Result: Of the 253 patients with SE who were included in the study, 39 (15.4%) died in the hospital. Using STESS 4 points to predict SE mortality, the area under the ROC curve (AUC) was 0.724 (P < 0.05). Using EMSE 79 points, the AUC was 0.776 (P < 0.05). To predict mortality in NCSE, STESS 2 points was used and resulted in an AUC of 0.632 (P > 0.05), while EMSE 90 points gave an AUC of 0.666 (P > 0.05). Conclusions: The hospital mortality rate from SE in this study was 15.4%. Those with STESS 4 points or EMSE 79 points had higher rates of SE mortality. Both STESS and EMSE are less useful predicting inhospital mortality in NCSE compared to CSE. Furthermore, the EMSE has some advantages over the STESS.
Background
Status epilepticus (SE) is one of the most common neurological emergencies. SE is a pathological condition characterized by persistent epileptic seizures that carries a high risk of morbidity and mortality. Rapid assessment of the patient's condition and risk of death is very important. This assessment should be objective and should be used to improve the quality of care and rational use of medical resources. The status epilepticus severity score (STESS) and the epidemiology-based mortality score in status epilepticus (EMSE) are two commonly used clinical evaluation tools to assess epilepsy status and prognosis. The scores can, to a certain extent, predict hospital morbidity and mortality. STESS [1, 11] uses the four parameters of consciousness, age, "worst" seizure type, and history of previous seizures to assess the risk of death in patients with SE. According to previous studies, STESS 3 points predicts poor functional outcomes (including hospital death or disability). However, more recent evidence has suggested that STESS 4 points better predicts poor outcomes. EMSE [2] includes additional variables such as aetiology, electroencephalogram (EEG) findings, co-morbidities, and other parameters. Thus, ESME takes more individual patient factors into account. Previous studies have shown that EMSE-ADLEG (EMSE-Age, Duration, Level of Consciousness, EEG) 58 points or EMSE-ECLEG (EMSE-Aetiology, Comorbidity, Level of Consciousness, EEG) 77 points can predict patient disability. EMSE-ADLEG 60 points or EMSE-ECLEG 81 points can predict hospital mortality. However, there are limitations for both scales in their ability to predict outcomes for convulsive status epilepticus (CSE) and non-convulsive status epilepticus (NCSE). The aim of this study was to determine the ability of these scales to predict hospital morbidity from SE in patients in western China.
Methods
This study included a total of 253 patients with SE who were admitted to the emergency department, neurological intensive care unit, neurology department, neurosurgery department, or another department at the West China Hospital of Sichuan University between January 2012 and January 2016. All patients were diagnosed according to the International League Against Epilepsy's (ILAE) most recent diagnostic criteria for status epilepticus [12] . The ILAE defines timepoint T1 SE as a seizure duration between 5 and 30 min, timepoint T2 SE as a seizure duration between 30 and 60 min, refractory SE as a seizure duration between 1 and 24 h, and a super-refractory SE as a seizure duration greater than 24 h [12] . Patients were required to have both clinical data and EEG data to be considered for inclusion. In accordance with the Declaration of Helsinki, participants in this study gave informed, voluntary consent to participate.
Inclusion criteria were: 1) age 18 years; 2) discharge diagnostic ICD-10 (International Classification of Diseases-10) with SE; 3) treated according to the American Epilepsy Society (AES) 2016 Status Epilepticus Guidelines [6] ; 4) provided voluntary and informed consent regarding the prognosis of epilepsy in patients with persistent SE.
Exclusion criteria were: 1) no EEG data or EEG data obtained at a time other than seizure onset, and 2) patients who did not provide informed consent.
The two scales used to predict in-hospital mortality were the EMSE (Table 1 ) and the STESS (Table 2 ). EMSE and STESS were calculated for all patients immediately after admission. The state of each patient's consciousness was assessed prior to the use of benzodiazepines. All patients with SE were treated according to the American Epilepsy Society (AES) 2016 Status Epilepticus Guidelines [6] . Treatment was as follows: in the first stage (6-20 min), the patient was given two benzodiazepines, such as Table 1 EMS (epidemiology-based mortality score in status epilepticus). intramuscular midazolam and an intravenous injection of diazepam. In the second stage (21-40 min), the patient was given intravenous sodium valproate. In the third stage, (41-60 min), the patient was given a dose of midazolam and propofol. Active treatment of both the primary disease and the symptoms was performed. SE was defined as either CSE or NCSE based on symptoms and EEG data. The time it took to gain seizure control was recorded, and patients were classified based on whether seizure control was gained after timepoint T1 or timepoint T2, or whether the seizure was refractory or super-refractory to treatment [6, 12] . EMSE and STESS were calculated again after the termination of the SE episode. The outcome variable of interest was in-hospital death.
Statistical analysis
Statistical analysis was performed using SPSS 22 and MedCalc statistical analysis software. The data are described using measures of central tendency. The area under the receiver operating characteristic (ROC) curve [15] (AUC) reflects the diagnostic value of the two scales: a value of 0.50-0.70 indicates low diagnostic value, a value of 0.70-0.90 indicates moderate diagnostic value, and a value greater than 0.90 indicates a high diagnostic value. A p-value of <0.05 was considered statistically significant. Sensitivity (true positive rate) is plotted as the ordinate on the ROC curve, while 1-specificity (false positive rate) is plotted as the abscissa. Maximizing the true positive rate while minimizing the false positive rate gives the best diagnostic criteria for the two scales.
Results

Descriptive statistics
This study included 253 patients with SE; of these, 39 (15.4%) patients died in the hospital (Table 3 ). The duration from SE to death was between 0 min and 10 days. Of the 253 patients, 105 (41.5%) were women. The ages ranged from 18 to 88 years old. A total of 212 (83.8%) patients were younger than 65 years of age. CSE was present in 207 (81.8%) patients; of these, 34 died in the hospital. The fatality rate among those with CSE was 13.4%. Ninetysix patients were classified as T1 time SE; of these, 12 died in the hospital, accounting for 4.7% of the patients included in the study. Fifty-two patients were classified as T2 time SE; of these, 8 people died, accounting for 3.2% of the total study population. Refractory SE was present in 58 people; of these, 13 people died in the hospital. Super-refractory SE was only found in one patient; this patient died in the hospital. NCSE was present in 46 people, 5 of whom died in the hospital. Two percent of the study population died from NCSE. Of the 253 patients included, 165 (65%) had no history of seizures or SE. Among those who experienced their first episode of SE during the study, 36 people died and 129 people survived. First seizure episodes of SE leading to death occurred in 14.2% of the study patients. Tracheal intubation was required for 66 (26.1%) patients. Of those who were intubated, 24 died. Abnormal EEG burst suppression was present in only 1 patient, while ASIDS/ LPDSs/GDPSS were found in 56 (22.1%). Thirty-six people had spontaneous remission of their SE. One stage of drug therapy was needed to terminate the seizures of 62 people. Two stages of drug therapy were needed in 78 people. Seventy-seven people required three stages of drug treatments to terminate their SE. When STESS was calculated, 9 people had 0 points, 7 people had 1 point, 75 people had 2 points, 28 people had 3 points, 110 people had 4 points, 6 people had 5 points, and 18 people had 6 points. When EMSE was calculated, 0 people scored <50 points, 22 people scored 50-59 points, 51 people scored 60-69 points, 40 people scored 70-79 points, 15 people scored 80-89 points, and 57 people scored >90 points. 
Predicting in-hospital death with the STESS and ESME scales
Out of 253 patients, the number of in-hospital deaths was 39. Using SPSS 22.0 and MedCalc ROC curves, a cut-off STESS of 4 points gave both a specificity and sensitivity of approximately 70%. The AUC was 0.724 (95% confidence interval [CI]: 0.642-0.806) with a standard error of 0.042 (p-value <0.0001). When an EMSE of 79 was used, the specificity and sensitivity were both approximately 70%. The AUC was 0.776 (95% CI: 0.707-0.846) with a standard error of 0.035 (p-value <0.0001). Using these cut-offs for the STESS and ESME gave moderate predictive ability (Fig. 1). 
Convulsive vs. non-convulsive status epilepticus
Patients with CSE made up 81.8% of the patients presenting with SE. Of the 207 patients with CSE, 34 (16.4%) died. Using STESS 4 points for those with CSE gave both a specificity and sensitivity of approximately 70% and an AUC of 0.730 (95% CI: 0.649-0.811; p < 0.0001). The predictive ability of the STESS was moderate. Using EMSE 76 points afforded a specificity of 70% and a sensitivity of 82%. The AUC was 0.81 (95% CI: 0.737-0.883; p < 0.0001), indicating moderate accuracy (Fig. 2) .
Forty-six patients presented with NCSE, of which 5 (10.9%) died in the hospital. Using STESS 2 points for those with NCSE gave both a specificity and sensitivity of approximately 70% and an AUC of 0.632 (95% CI: 0.370-0.893; p = 0.341). EMSE 90 points was used as the cut-off for NCSE and afforded a specificity of 61% and a sensitivity of 80%. The AUC was 0.666 (95% CI 0.512-0.798; p = 0.169) (Fig. 3) .
Time point T1 vs. T2 vs. refractory vs. super-refractory CSE
Convulsive status epilepticus resolved by time point T1 in 96 patients. Of these, 12 people died in the hospital. For those with resolution by time point T1, STESS 4 points gave both a specificity and sensitivity of approximately 70% and an AUC of 0.792 (95% CI: 0.663-0.919; p = 0.001). EMSE 76 points gave a specificity of 86% and a sensitivity of 67%. The AUC was 0.788 (95% CI 0.647-0.928; p = 0.001). Both STESS and EMSE had moderate predictive accuracies for those with CSE who had SE resolution by time point T1 (Fig. 4) .
Fifty-two patients had seizure termination by time point T2. Of the 52, 8 died in the hospital. Using STESS 4 points gave both a specificity and sensitivity of approximately 70%. The AUC was Fig. 1 . Total. Refractory SE occurred in 58 people, of which 13 died in the hospital. One patient had super-refractory SE and died in the hospital. Using STESS 4 points for refractory or super-refractory SE gave both a specificity and sensitivity of approximately 70%. The AUC was 0.656 (95% CI: 0.519-0.794; p = 0.079). Using EMSE 80 points gave both a specificity and sensitivity of 70%. The AUC was 0.792 (95% CI: 0.674-0.910; p = 0.001; Fig. 6 ).
Discussion
Status epilepticus is a common neurological emergency that can lead to permanent neurological damage, disability, and death. The annual incidence of SE in populations from southern Europe is as high as 27.2/10,000 people. In the present study, males comprised 58.5% of patients presenting with SE. According to reports from locations outside of China, sustained SE carries a mortality rate ranging from 3 to 33% [7, 8, 9, 10, 13, 14, 16, 20] . In southwest China, the mortality rate from SE has been reported to be approximately 15.8% [20] . In our study, 253 patients were hospitalized with SE and 39 died in the hospital, resulting in a mortality rate of 15.4%. While this mortality rate is higher than that reported in other countries, it is consistent with previous studies from southwest China. Despite the improvements in medical technology, the in-hospital mortality of patients with SE in western China has not decreased significantly. There are several potential reasons why a decrease in in-hospital mortality compared to previous reports was not seen in the present study. First, this study included patients with NCSE, who are not typically included in studies regarding mortality from SE. Second, in accordance with the latest classification of SE, this study included patients with SE at time point T1. Thus, the scope of inclusion and sample size were expanded compared with previous studies. The latest epileptic status, which is included in the T1 time of SE, and the amount of patients included in the sample, along with the scope of the study, were expanded compared with previous studies. Third, we included patients with SE from diverse aetiologies. For SE caused by cancer, lupus encephalopathy, or autoimmune encephalitis, or when the aetiology is unknown, definitive treatments are still lacking. Fourth, refractory and superrefractory SE carry an extremely high hospital mortality [13, 17, 18] . Although many studies have been performed and have provided some clear and effective guidelines for reducing the incidence of SE, some previously proposed treatments, such as low-temperature therapy, electrotherapy, and the ketogenic diet lack definitive supporting evidence and likely warrant further study.
In-hospital mortality has been closely related to seizure aetiology [9, 10, 19, 21] . More than one-third (36%) of SE patients had a previous history of epilepsy, with triggering factors that included non-standard use of antiepileptic drugs (including selfmedication, frequent drug changes, etc.), systemic infection, a metabolic disorder, or consumption of a common seizure inducer, such as alcohol. Nearly two-thirds (65%) of SE patients had no previous history of epilepsy. The main causes for SE included central nervous system infections, immune disorders, tumours, head trauma, acute vascular disease, hypoxic encephalopathy, metabolic diseases, and poisoning. According to the literature, potentially fatal events, such as a severe stroke, acute severe central nervous system infection, or rapid progression of an intracranial malignancy, are more common in patients with SE and are significantly associated with in-hospital death. Preoperative mortality in SE patients without a history of epilepsy was higher than mortality in SE patients with a history of epilepsy.
This study shows that using either the STESS or EMSE scale to evaluate SE prognosis is practical. STESS 4 points and EMSE 74 points predicted hospital death in those with SE. Compared with the previously suggested STESS cut-off of 3 points, using a cut-off of 4 points was more specific for poor prognosis. It is also practical to use both the STESS and EMSE scales to evaluate CSE prognosis. However, there are limitations in using these scales to evaluate prognosis of NCSE. For patients with NCSE, the EMSE was better at predicting prognosis than the STESS. The STESS only includes the patient's age, state of consciousness, type of attack, and previous history of epilepsy. Since most patients with NCSE are in a state of consciousness that is awake or confused, most would score an STESS of 2 points; thus the STESS is less able to distinguish between those with good and poor prognosis in cases of NCSE. The EMSE takes into account the aetiology and EEG findings; these factors have been found to be particularly important when evaluating SE prognosis. As there is currently not a more reliable scale to evaluate patients with NCSE, the EMSE, though not perfect, is still useful. the EMSE was more predictive of prognosis than the STESS. In general, the STESS and EMSE are useful tools for clinicians to evaluate the prognosis of SE, but individualized analysis is needed.
This study only evaluated the outcome of death and did not include other variables regarding physical disability or long-term quality of life after discharge. Further longitudinal research that includes long-term follow-up is warranted. The duration from SE to death was 0 min-10 days, which is difficult to quantify, and thus, duration was not included in the analysis. Furthermore, the two scales rely on doctors' judgements and are therefore subject to bias. Improved scales or indicators are required to determine the overall prognosis for patients with SE. Larger, multi-centre studies are warranted to further explore SE outcomes. To avoid the inaccuracy regarding time points T1 and T2 in SE which occurs at home or outside of the hospital, we removed the patients whose SE occurred outside the hospital and re-analysed the data (Fig. 7) .
Conclusion
The in-hospital mortality rate of patients with SE in western China was approximately 15.4%. Males had a higher prevalence of SE than females (58.5% male vs. 41.5% female). The STESS and EMSE scales could be used to predict in-hospital mortality from status epilepticus; in particular, STESS 4 points and EMSE 79 points to predicted patients with higher mortality risk. Thus, the EMSE and STESS are useful in predicting the prognosis of patients with SE in western China. The EMSE may be better than the STESS at predicting in-hospital mortality of patients with NCSE and refractory or super-refractory SE.
